A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemother-Reference-Cited by-同舟云学术

A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemother

Published:2016-03-21 Issue:3 Volume:35 Page:288-295
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Matsumoto Takuro¹,Hara Takeshi¹,Shibata Yuhei¹,Nakamura Nobuhiko¹,Nakamura Hiroshi¹,Ninomiya Soranobu¹,Kitagawa Junichi¹,Kanemura Nobuhiro¹,Goto Naoe¹,Kito Yusuke²,Kasahara Senji³,Yamada Toshiki⁴,Sawada Michio⁵,Miyazaki Tatsuhiko⁶,Takami Tsuyoshi²,Takeuchi Tamotsu²,Moriwaki Hisataka¹,Tsurumi Hisashi¹

Affiliation:

1. Department of Hematology; Gifu University Graduate School of Medicine; Gifu Japan

2. Department of Pathology and Translational Research; Gifu University Graduate School of Medicine; Gifu Japan

3. Department of Hematology; Gifu Municipal Hospital; Gifu Japan

4. Department of Hematology; Gifu Prefectural General Medical Center; Gifu Japan

5. Department of Hematology; Japanese Red Cross Gifu Hospital; Gifu Japan

6. Pathology Division; Gifu University Hospital; Gifu Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hon.2285/fullpdf

Reference30 articles.

1. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

2. Current trends in large cell lymphoma;Fisher;Leukemia,2003

3. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60);Pfreundschuh;Lancet Oncol,2008

4. Ifosfamide, carboplatin and etoposide: a highly effective cytoreduction and peripheral blood progenitor cell mobilization regimen for transplant-eligible patients with non-Hodgkins lymphoma;Moskowitz;J Clin Oncol,1999

5. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy;Cabanillas;Blood,1982

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non‐Hodgkin lymphoma;Hematological Oncology;2023-11-06

2. PD-1 blockade combined with ICE regimen in relapsed/refractory diffuse large B-cell lymphoma;Annals of Hematology;2023-06-12

3. Clinical significance of oxidative stress for untreated patients with diffuse large B‑cell lymphoma;Molecular and Clinical Oncology;2021-11-04

4. Follicular lymphoma suggested to transform into EBV-negative plasmablastic lymphoma;International Journal of Hematology;2019-03-11

5. Recognition of Non-Hodgkin Lymphoma of the Maxilla;Journal of the California Dental Association;2018-12-01